2-(naphthalen-2-yl)ethanethiol | 91720-78-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(naphthalen-2-yl)ethanethiol
• 英文别名: 2-(2-Mercapto-ethyl)-naphthalin；2-(2-Naphthyl)ethanethiol；2-naphthalen-2-ylethanethiol
• CAS: 91720-78-4
• 化学式: C₁₂H₁₂S
• mdl: MFCD11521148
• 分子量: 188.293
• InChiKey: GPXNBMMDNQAKHZ-UHFFFAOYSA-N

物化性质

• 沸点：
  188-189 °C(Press: 15 Torr)
• 密度：
  1.111 g/cm3(Temp: 24 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(naphthalen-2-yl)ethanethiol 在 palladium on activated charcoal 氢气 作用下， 生成 (4R,5S,6S)-6-((R)-1-Hydroxy-ethyl)-4-methyl-3-(2-naphthalen-2-yl-ethylsulfanyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid
  参考文献：
  名称：

  Synthesis and antibacterial activity of lipophilic carbapenems with anti-MRSA activity

  摘要：

  A series of sulphur-linked and carbon-linked lipophilic carbapenems has been prepared and evaluated for antibacterial activity in vitro and in vivo and for affinity for PBP2' of Staphylococcus aureus. Potent activity in vitro against methicillin-resistant S. aureus and methicillin-resistant coagulase negative staphylococci was observed despite IC50 values for PBP2' being higher than the MIC. Copyright (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00450-7
• 作为产物：
  描述：

  2-乙烯基萘 在 偶氮二异丁腈 、 三苯基硅烷硫醇 、 三氟乙酸 作用下， 以 苯 为溶剂， 反应 1.0h， 生成 2-(naphthalen-2-yl)ethanethiol
  参考文献：
  名称：

  EP1431267

  摘要：

  公开号：

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A₂ Guided by Molecular Dynamics and Structure–Activity Relationships
  作者：Varnavas D. Mouchlis、Dimitris Limnios、Maroula G. Kokotou、Efrosini Barbayianni、George Kokotos、J. Andrew McCammon、Edward A. Dennis

  DOI：10.1021/acs.jmedchem.6b00377

  日期：2016.5.12

  The development of inhibitors for phospholipase A2 (PLA2) is important in elucidating the enzymes implication in various biological pathways. PLA2 enzymes are an important pharmacological target implicated in various inflammatory diseases. Computational chemistry, organic synthesis, and in vitro assays were employed to develop potent and selective inhibitors for group VIA calcium-independent PLA2.

  磷脂酶A 2（PLA 2）抑制剂的开发对于阐明酶在各种生物学途径中的意义很重要。PLA 2酶是与多种炎性疾病有关的重要药理靶标。计算化学，有机合成和体外测定法被用来为VIA组钙独立的PLA 2开发有效的和选择性的抑制剂。研究了一组氟酮抑制剂与两种人胞质PLA 2酶（IVA cPLA 2组和VIA iPLA 2组）的结合方式。合成了新化合物，并针对三种主要PLA 2进行了分析s。这项研究导致了针对GVIA iPLA 2的四种有效的和选择性的硫醚氟代酮抑制剂以及硫醚酮1,2,4-恶二唑抑制剂的开发，它们将作为未来开发和研究的先导化合物。具有硫醚的1,2,4-恶二唑酮官能团是一种新颖的结构，它将被用作开发具有更高效力和对GVIA iPLA 2选择性的抑制剂的先导。
• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• Boron Containing PDE4 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20200108083A1

  公开（公告）日：2020-04-09

  The present invention relates to boron containing compounds of Formula (I) X—Y—Z   Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

  本发明涉及具有化学式（I）X—Y—Z的含硼化合物，化学式（I）抑制磷酸二酯酶4（PDE4）。该发明还涵盖含有这些化合物的药物组合物以及通过抑制PDE4治疗疾病、症状或障碍的方法。